• By Donald Zuhn

    Patents for HumanityOn Thursday, the U.S. Patent and Trademark Office announced the latest winners of the Patents for Humanity program.  The Patents for Humanity program, which was launched by the Office in February 2012 as part of an Obama Administration initiative to promote game-changing innovations to solve long-standing development challenges, is a competition recognizing patent owners and licensees who address global challenges in health and standards of living.  Entrants are divided into five categories:  medicine, nutrition, sanitation, energy, and living standards.  The Office noted that in this latest round, for which the application process concluded on December 4, 2015, four of the five categories did not produce honorees.  Winners receive accelerated processing of select matters at the USPTO (i.e., a patent application, ex parte reexamination, or an ex parte appeal to the Patent Trial and Appeal Board) in addition to recognition for their work.  The latest winners are as follows:

    • The U.S. Food & Drug Administration for developing an improved meningitis vaccine production process, which has been used to immunize 235 million people in high-risk African countries.  FDA scientists set out to create a better meningitis vaccine production method for the Meningitis Vaccine Program (MVP), which was formed by the health non-profit PATH, the Gates Foundation, and the World Health Organization to combat Meningitis A.  The new technology developed by the FDA raised vaccine production yield from 20% to 60% and enabled the vaccine to last up to four days without refrigeration, unlike previous vaccines.  The FDA has licensed the technology to the MVP.

    • Case Western Reserve University (CWRU) for creating a low-cost, accurate malaria detection device, which allows for better diagnosis and treatment of malaria.  CWRU Engineers and doctors designed the Magneto-Optical Detection (MOD) device, which uses lasers and magnets to diagnose malaria by detecting iron-laden byproducts of the parasite in the blood.  The device can be ten times cheaper per test than the current standard.  CWRU received an honorable mention in the 2014 Patents for Humanity program.

    • GestVision for developing a quick, simple diagnostic test for preeclampsia, a pregnancy complication that is the leading cause of prenatal death for mothers and babies worldwide, mostly in low and middle income countries.  GestVision's test detects misfolded proteins in urine associated with PE, which may be shown by a colored dot similar to a pregnancy test.  Following initial research at Yale University, GestVision was created to further develop the technology.

    • The Global Good Fund at Intellectual Ventures for creating a passive cooler that can keep vaccines cold over thirty days, and for donating dozens of units to the fight against Ebola and other relief efforts.  Researchers at Global Good designed the Arktek cooler to keep vaccines cold for over a month with no power required — the device uses high-efficiency insulation materials to prevent heat transfer.  The technology has been licensed to a leading refrigeration manufacturer in order to scale production of the device at an affordable price.

    This year, the Office also awarded two honorable mentions:

    • Sanofi for researching new malaria drug candidates with shorter, simpler treatment regimens that can potentially counter the growing trend of drug resistance.

    • Alere Inc. for developing diagnostic assays for rapid and early HIV diagnosis at the point of care in low-resource settings.

    Additional information regarding the latest winners of the Patents for Humanity program can be found here, and information regarding the Patents for Humanity program can be found here.

  • CalendarOctober 3-4, 2016 – Advanced Patent Law Seminar (Chisum Patent Academy) – Washington, DC

    October 13, 2016 – "Leveraging USPTO Examiner Count System: Efficiently Prosecuting Patents, Lowering Prosecution Costs" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 18, 2016 – "Brexit: The Impact on Your International Patent Filing Strategy" (RWS inovia and Managing IP) – 9:00 am (CT)

    October 19, 2016 - Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) – Alexandria, VA

    October 19, 2016 – "To Patent or Not to Patent: When to Keep Your IP a Trade Secret" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    ***Patent Docs is a media partner of this conference or CLE

  • RWS GroupRWS inovia and Managing IP will be offering a free webinar on "Brexit: The Impact on Your International Patent Filing Strategy," on October 18, 2016 at 9:00 am (CT).  Reinhard Ottway of RWS Group; Gary Smith, former director of the PCT at WIPO; Justin Simpson of Inovia; and James Nurton, managing editor, Managing IP will discuss Brexit and implications for the Unitary Patent (UP), the Unitary Patent Court (UPC), and other important patent related issues.

    Managing Intellectual PropertyThose interested in registering for the webinar can do so here.

  • USPTO SealThe U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on October 19, 2016 at the USPTO Headquarters (Alexandria, VA).  The agenda for the meeting is as follows:

    • Welcoming and Opening Remarks (10:00 – 10:10 am EDT) — Jerry Lorengo, Director, TC1600, USPTO; Daniel Sullivan, Director, TC1600, USPTO; and Wanda Walker, Director, TC1600, USPTO

    • Writing a 35 USC 112(a)-Enablement Rejection for Methods of Treatment with Organic Compounds (10:10 – 11:00 am) — Bennett Celsa, QAS, TC1600, USPTO; Sreeni Padmanabhan, SPE, TC1600, USPTO

    • Claim Interpretation (11:00 – 11:45 am) — Jeffrey Lundgren, SPE, TC1600, USPTO

    • Lunch (11:45 am – 12:55 pm)

    • Functional Claiming in the Life Sciences (12:55 – 1:45 pm) — Joe Mallon, Partner, Knobbe, Martens, Olson & Bear, LLP

    • Enhanced Patent Quality Initiative (EPQI) (1:45 – 2:30 pm) — Andrea Wellington, Senior Advisor, Office of the Deputy Commissioner for Patent Quality, USPTO

    • Break (2:30 – 2:40 pm)

    • Rule 130 Declarations for First-Inventor-to-File Applications (2:40 – 3:25 pm) — Kathleen Fonda, Senior Legal Advisor, Office of Patent Legal Administration (OPLA), USPTO

    • Special Programs for Patent Prosecution (3:25 – 4:00 pm) — Fereydoun Sajjadi, SPE, TC1600, USPTO

    • Closing Remarks (4:00 – 4:10 pm) – Directors, TC1600, USPTO

    Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.

  • CBM Petition Denied for Patent Lacking Financial Product or Financial Activity in the Claims

    By Joseph Herndon

    USPTO SealIn a recent decision, the Patent Trial and Appeal Board (PTAB) denied the institution of a covered business method (CBM) patent review on an Internet Portal System patent because the claims lacked any recitation of a financial product or financial activity.  The decision serves well to inform petitioners that the focus for CBM decisions is becoming more on the claim language itself, in contrast to some earlier decisions by the Board where a liberal reading and interpretation of the patent in general was allowed to institute a CBM trial.

    Plaid Technologies Inc. filed a Petition requesting a review under the transitional program for CBM patents of claims 1–12 of U.S. Patent No. 6,199,077 owned by Yodlee, Inc.  Ultimately, the PTAB determined that the information presented in the Petition did not establish that the '077 patent qualifies as a "covered business method patent" that is eligible for review.

    The '077 patent

    The '077 patent generally relates to the field of Internet navigation and, in particular, to a method and apparatus for gathering summary information from users or websites and presenting that information as HyperText Markup Language to the users or websites via either push or pull technology.  According to the '077 patent, one problem encountered by an individual who has several subscriptions to Internet-brokered services is that there are numerous passwords and usernames to remember.  Another problem encountered by an individual with numerous subscriptions services is that he/she must bookmark all the corresponding web pages in a computer cache so he/she can find and access these services quickly.  The '077 patent purportedly addresses these problems by providing an Internet portal that includes a server connected to the Internet, along with portal software executing on the server that includes a summary software agent.  The Internet Portal maintains a list of Internet websites specific to a particular user, and the summary software agent accesses these websites, retrieves information according to pre-programmed criteria, and then summarizes the retrieved information for delivery to the user.

    Of the challenged claims, claims 1 and 7 are independent.  Claim 1 is directed to an Internet portal, whereas claim 7 is directed to a method executed in an Internet portal system for gathering data specific to a person from a plurality of Internet sites storing data specific to that person.  Claims 1 and 7 are reproduced below:

    1.  An Internet Portal, comprising:
        an Internet-connected server;
        a list of addresses of Internet sites associated with a specific person, which sites store information specific to the person; and
        a software suite executing on the server, the software suite including a set of gathering spitware agents, with at least one gatherer agent dedicated to each of the Internet sites;
        wherein the Portal accomplishes a gathering cycle by accessing individual ones of the Internet sites, authenticating too each site accessed as the person, and the gathering agent dedicated to each site accessed extracts data from that site.

    7.  In an Internet Portal system, a method for gathering data specific to a person from a plurality of Internet sites storing data specific to that person, the method comprising the steps of:
        (a) initiating a gathering cycle accessing individual ones of the plurality of sites;
        (b) authenticating to the sites as the person; and
        (c) executing a software gathering agent at each site accessed to gather data from the site, the gathering agent dedicated to each site accessed.

    Does the '077 patent qualify for CBM review?

    A "covered business method patent" is a patent that "claims a method or corresponding apparatus for performing data processing or other operations used in the practice, administration, or management of a financial product or service, except that the term does not include patents for technological inventions."  AIA § 18(d)(1).  For purposes of determining whether a patent is eligible for a covered business method patent review, the focus is on the claims.

    Although not binding authority, several Board decisions have determined that the following considerations weigh in favor of concluding that the patent at issue is not a CBM patent eligible for review:  (1) claims of general utility with (2) no explicit or inherent finance-related terminology or limitations.  (Qualtrics, LLC v. OpinionLab, Inc., Case CBM2015-00164 (PTAB Feb. 3, 2016)).

    Plaid contended that the challenged claims of the '077 patent cover financial-related activities because these claims gather data for "subscription services," such as activities like "banking, stock trading, shopping, and so forth."  For instance, Plaid argued that the claimed "Internet Portal system" is intended to be used to gather data, particularly financial data, because the corresponding "Internet sites" may include a number of financially-related websites, such as "My Bank.com," "My Stocks.com," "My shopping.com," "Mortgage.com," and "Airline.com."

    Yodlee, however, argued that the arguments presented by Plaid narrowly focus on examples in the specification of the '077 patent, and that there is not a single claim term that is tied sufficiently to a financial-related activity that would justify concluding that the '077 patent is a CBM patent eligible for review.

    The PTAB agreed with Yodlee and found that Plaid had not demonstrated that the challenged claims of the '077 patent are directed to a method or apparatus for performing data processing or other operations used in the practice, administration, or management of a financial product or service.

    The language of the independent claims generally applies to executing a software program to gather or extract data from a plurality of websites on the Internet.  Given this general utility, the PTAB agreed with Yodlee that the independent claims are devoid of any claim terms that reasonably could be argued as being tied sufficiently to a financial-related activity that would justify concluding that the '077 patent is a CBM patent eligible for review.

    Although certain examples in the specification of the '077 patent cover financial embodiments, the PTAB found no language in the specification that somehow limits the scope of claims 1 and 7 in this way.  Indeed, the specification discloses that the list of websites on a user's personalized web page, which may include "My Bank.com," "My Stocks.com," "My shopping.com," "Mortgage.com" and "Airline.com," are "but a few of many exemplary destinations that may be present and listed on [the user's personalized web page]."

    Lastly, the PTAB noted the Board panel's reasoning in Qualtrics applies equally to the circumstances presented in this case.  That is, if the PTAB were to adopt the position advocated by Plaid in its Petition, it would mean that any patent claiming something that might potentially apply to a financial product or service would be a CBM patent eligible for review, regardless of its general utility and application outside of finance.

    Thus, the PTAB was clear that because the challenged claims of the '077 patent are of general utility with no explicit or inherent finance-related terminology or limitations, this patent was not considered a CBM patent eligible for review.  The CBM review was thus not instituted.

    Before Administrative Patent Judges Kevin F. Turner, Michael R. Zecher, and John A. Hudalla
    Decision by Michael R. Zecher

  • CBM Patent Review Denied for Claims Lacking Financial Subject Matter

    By Joseph Herndon

    USPTO SealThe PTAB denied institution of a covered business method (CBM) patent review in a case between BMC Software Inc. (Petitioner) v. zIT Consulting GmbH (Patent Owner).  Petitioner, BMC Software, Inc., filed a Petition to institute a CBM patent review of claims 1–29 of U.S. Patent No. 8,904,405, owned by zIT Consulting GmbH.  While the '405 patent specification mentioned some example usages in the financial sector, because the claims lacked any mention of financial subject matter, the PTAB denied the CBM patent review.

    The '405 Patent

    The '405 patent, titled "System and Method for Managing Mainframe Computer System Usage," issued on December 2, 2014.  The patent relates to managing mainframe computer system usage for large mainframe computers.  More particularly, it relates to managing processing limits of logical partitions executed by such computers.  The Background of the Invention refers specifically to IBM's System z computing platform.  According to the patent, IBM allows System z users to manually set a usage limit, referred to as a Defined Capacity (DC), for each logical partition (LPAR).  IBM also allows users to manually set a usage limit for a group of LPARs, referred to as a Group Capacity Limit (GCL).

    One objective of the patent is to manage computer system workload performance for System z, and to control costs by managing usage of the system using DCs and GCLs.

    The invention thus uses a logically partitioned data processing system, and each running workload task can be classified based on time criticality with groups of logical partitions being freely defined as having processing capacity limits and upon a determination of how much capacity is needed for a time critical workload task, the workload can be balanced between logical partitions to prevent surplus processing capacity being used to run not time critical workloads.

    Of the challenged claims, claim 1 is representative and reproduced below:

    1.  A method for managing mainframe computer system usage comprising:
        establishing a first group definition, the first group definition including first and second logical partitions executed by the mainframe computer system;
        establishing a first group policy, the first group policy including first and second partition processing capacity limits, and a time criticality level for each of a plurality of workload tasks assigned to the first and second logical partitions, each time criticality level indicating whether the workload task associated therewith is time critical or not time critical;
        monitoring performance of the first and second logical partitions in executing the plurality of workload tasks;
        determining, based on the performance monitoring and the first group policy, if either of the first and second logical partitions has a capacity deficit or a capacity surplus; and
        if one of the first and second logical partitions is determined to have a capacity deficit while the other is determined to have a capacity surplus, automatically balancing the first and second partition processing capacity limits.

    Whether the '405 Patent Is a Covered Business Method Patent

    The standard for instituting a covered business method patent review is set forth in 35 U.S.C. § 324(a), which states that the petition must demonstrate that it is more likely than not that at least 1 of the claims challenged in the petition is unpatentable.

    But a threshold question is whether the '405 patent is a "covered business method patent," as defined by the AIA.  The PTAB found that it was not.

    A covered business method patent is "a patent that claims a method or corresponding apparatus for performing data processing or other operations used in the practice, administration, or management of a financial product or service." AIA § 18(d)(1).

    Petitioner argued that the '405 patent meets the requirement of the statute because it claims a method used in the management of a financial product, namely, a method described as being for managing IBM's software licensing contract which is argued to be a "financial product."

    The PTAB disagreed.  The PTAB noted that the '405 patent describes the Field of Invention as "managing mainframe computer system usage, and more particularly, . . . managing processing capacity limits of logical partitions executed thereby."  Consistent with this description, the independent claim preambles each recite, "A method for managing mainframe computer system usage."  The PTAB concluded that the patent is not directed to managing a software license contract, but rather to managing the physical usage of a computer system.  The mere fact that by managing usage, certain costs may be reduced, does not meet the criteria of the statute.  The PTAB stated that saving money is not necessarily a financial activity under the covered business method patent review statute, and if it were, then every patent that led to a cost reduction would qualify for CBM review.  In fact, virtually every patented invention is intended to confer a financial benefit on its user, and so, the statute cannot be read to be this broad.

    Petitioner secondly argued that the '405 patent targets a tool specifically designed for the financial sector, i.e., System z.  Here, the '405 patent states "a trend toward more commercial computer users owning and operating their own computer systems," and lists as examples, very large corporations, and especially financial sector corporations such as banks, exchanges, brokerages and the like.  The '405 patent goes on to identify IBM as the preeminent example of a third party provider of computing services, and specifically identifies IBM's System z.  From this, Petitioner concluded that in at least these two senses, the claims target a method to manage a financial product.

    The PTAB again was unpersuaded by this second argument because the claims are "directed to" managing usage of a computer system.  There is nothing in the Specification or claims that requires a particular computer system or industry.  By referring to banks, exchanges, brokerages, and the like, the '405 patent does not limit the invention to a particular industry or application.

    The Petitioner conceded that the '405 patent claims on their face, do not recite a financial limitation, but attempted to analogize this case to others in which the PTAB found claims to be CBM qualified.  While the PTAB in this instance recognized that other panels have considered evidence of the problem addressed in the specification in determining eligibility for CBM review, the PTAB declined to be bound by the particular factors considered in those cases or by the outcomes.

    The PTAB then cited to other panels of the Board having similar facts that reached an opposite conclusion from that urged by Petitioner.  See, e.g., AT&T Mobility LLC v. Intellectual Ventures II LLC, Case CBM2015-00185 (PTAB May 4, 2016).  In AT&T, for example, the Board indicated that statements in the specification that a claimed invention has particular utility in financial applications may weigh in favor of determining that a patent is eligible for a covered business patent review; however, CBM patent review is not necessarily available for patents that claim generally useful technologies that also happen to be useful to financial applications.  Thus, focus was on the claims, and what the claims were "directed to", in contrast to possible uses of the claimed invention.

    In short, the PTAB was not persuaded by Petitioner's argument that the '405 patent claims are directed to methods for performing data processing or other operations used in the practice, administration, or management of a financial product or service.  Thus, the Petition for CBM review was denied.

    This is a nice decision by the PTAB here to follow the requirements of the statute that the claims need to be directed to a financial product or service, rather than following prior Board panels that liberally allow CBM review basically in any instance in which the patent mentions something financial.

    Before Administrative Patent Judges Justin T. Arbes, Thomas L. Giannetti, and Kerry Begley
    Decision by Thomas L. Giannetti

  • By John Cravero and Richard Martin

    USPTO SealAbout the PTAB Life Sciences Report:  Each week we will report on recent developments at the PTAB involving life sciences patents.

    Medtronic Xomed, Inc. v. Neurovision Medical Products, Inc.

    PTAB Petition:  IPR2016-01847; filed September 19, 2016

    Patent at Issue:  U.S. Patent No. 8,467,844 ("Electrode for prolonged monitoring of laryngeal electromyography," issued June 18, 2013) claims a device for use in monitoring electrical signals during laryngeal electromyography.

    Petitioner Medtronic Xomed, Inc. is challenging the '844 patent on two grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '844 patent is involved in litigation in the Eastern District of Texas, captioned Neurovision Medical Products, Inc v. Medtronic Public Limited Company et al., 2:16-cv-00127.


    HyperBranch Medical Technology, Inc. v. Incept LLC

    PTAB Petition:  IPR2016-01836; filed September 16, 2016

    Patent at Issue:  U.S. Patent No. 7,009,034 ("Biocompatible crosslinked polymers," issued March 7, 2006) claims a method of preparing a composition suitable to coat a tissue of a patient where nucleophilic functional groups and electrophilic functional groups crosslink to form a hydrogel.

    Petitioner HyperBranch Medical Technology is challenging the '034 patent on six grounds as being anticipated under 35 U.S.C. § 102(b) (grounds 1 and 4) or obviousness under 35 U.S.C. § 103(a) (grounds 2, 3, 5, and 6).  View the petition here.

    Related Matters:  According to the petition, the '034 patent is involved in litigation in the District of Delaware, captioned Integra LifeSciences Corp., et al., v. HyperBranch Med. Tech., Inc., 15-819-LPS- CJB.


    Natus Medical Incorporated v. Nox Medical EHF

    PTAB Petition:  IPR2016-01822; filed September 15, 2016

    Patent at Issue:  U.S. Patent No. 9,059,532 ("Biometric belt connector," issued June 16, 2015) claims an electrode belt and belt connector for electrically connecting a conductor of the electrode belt to a male portion of a snap connector electrode connected to a biometric device.

    Petitioners Natus Medical Inc., Natus Neurology Inc., Embla Systems LLC, and Embla Systems LTD. are challenging the '532 patent on eight grounds as being anticipated under 35 U.S.C. § 102(b) (ground 1) or obviousness under 35 U.S.C. § 103(a) (grounds 2-8).  View the petition here.

    Related Matters:  According to the petition, the '532 patent is involved in litigation in the District of Delaware, captioned Nox Medical Ehf. v. Natus Neurology Inc., Civil Action No. 15-709-RGA.


    Minerva Surgical, Inc. v. Hologic, Inc.

    PTAB Petition:  IPR2016-00680; filed March 4, 2016; institution denied September 12, 2016

    Patent at Issue:  U.S. Patent No. 9,095,348 ("Moisture transport system for contact electrocoagulation," issued August 4, 2015) claims a device for ablating the interior linings of body organs such as the uterus.

    Petitioner Minerva Surgical Inc. challenged the '348 patent on two grounds as being obviousness under 35 U.S.C. § 103(a).  View the petition here.  The PTAB denied institution of Inter Partes Review stating that Petitioner did not show a reasonable likelihood that it would prevail with respect to at least one of the challenged claims.  View the PTAB Decision here.

    Related Matters:  According to the petition, the '348 patent is involved in litigation in the District of Delaware, captioned Hologic, Inc. et al v. Minerva Surgical, Inc., 1:15-cv-01031-SLR.  The petition also indicates that the '348 patent is involved in IPR2016-00685 (Petitioner Minerva; filed on 03/04/2016; Institution denied 09/12/2016).


    Minerva Surgical, Inc. v. Hologic, Inc.

    PTAB Petition:  IPR2016-00685; filed March 4, 2016; institution denied September 12, 2016

    Patent at Issue:  U.S. Patent No. 9,095,348 ("Moisture transport system for contact electrocoagulation," issued August 4, 2015) claims a device for ablating the interior linings of body organs such as the uterus.

    Petitioner Minerva Surgical Inc. challenged the '348 patent on one ground as being obviousness under 35 U.S.C. § 103(a).  View the petition here.  The PTAB denied institution of Inter Partes Review stating that Petitioner did not show a reasonable likelihood that it would prevail with respect to at least one of the challenged claims.  View the PTAB Decision here.

    Related Matters:  According to the petition, the '348 patent is involved in litigation in the District of Delaware, captioned Hologic, Inc. et al v. Minerva Surgical, Inc., 1:15-cv-01031-SLR.  The petition also indicates that the '348 patent is involved in IPR2016-00680 (Petitioner Minerva; filed on 03/04/2016; Institution denied 09/12/2016).

  • "Computer Display System" Patent Found Invalid under § 101

    By Joseph Herndon

    District Court for the Northern District of CaliforniaTridim Innovations LLC sued Amazon.com, Inc. for patent infringement of U.S. Patent Nos. 5,838,326 and 5,847,709 in the U.S. District Court for the Northern District of California.  Amazon moved to dismiss TriDim's claims for invalidity under 35 U.S.C. § 101.  The District Court granted the motion to dismiss finding that the patents are directed to ineligible subject matter under section 101.  Despite the patents claiming a "computer controlled display system", such claims were found to be directed to an abstract idea that lacked any inventive concept.

    Inventors from the Xerox Corporation filed the '326 and '709 patents in separate applications on September 26, 1996, and TriDim obtained assignment of the patents.  The only claims at issue here are claim 14 of the '326 patent and claims 1 and 9 of the '709 patent.

    The two patents have almost identical summaries and specifications.  They both describe a three dimensional document workspace for interacting with large numbers of document objects, designed to help balance the necessary tradeoffs of rapid access, number of collections and associated documents, and available screen space.  Specifically, the patents provide a system for "hierarchically" dividing a computer workspace for documents into three areas depending on the user's "interaction rates" with certain documents: (1) "focus space" where direct interaction with a document object occurs; (2) "immediate memory space" where document objects that are in use, but not currently being interacted with are placed; and (3) "tertiary space" where many document objects that are not currently in use are placed.  In the specification, the patentee analogizes these spaces, respectively, to (1) a "desk" where documents in use are placed, (2) a space behind the desk where objects are depicted as "smaller in size" as they get a further "distance back (i.e. in the z-direction)," and (3) a "bookshelf" for items not currently in use.

    Each of the asserted claims describes a "computer controlled display system" with these features.  For example, claim 14 of the '326 patent, which is typical of the asserted claims in both patents, covers:

    1.  A computer controlled display system for displaying document objects in a three-dimensional document workspace on a display, said computer controlled display system comprising:
        document receiving means for receiving document objects;
        positioning means for receiving user input for positioning document objects within said three-dimensional document workspace;
        workspace display circuitry for generating display information for displaying said three-dimensional document workspace and said document objects, said workspace display circuitry comprising:
        circuitry for displaying a focus space, said focus space for detail display of a document object;
        circuitry for displaying an immediate space, said immediate space for ephemeral positioning of document objects that are in use but not in focus; and
        circuitry for displaying a tertiary space, said tertiary space for positioning document objects that are not in use.

    The District Court noted that the patents do not involve special software or hardware of any type, and that the specification describes that the system and gestures can be used on a "Silicon Graphics workstation," as this system "provides for generating software programs which manipulate graphical objects in a three dimensional space, so description of programming techniques for rendering graphical objects in a three dimensional space is not deemed necessary".

    In addition, the patents state that a person of skill in the art could implement the invention on any commercially available computer with the functionality for manipulating graphical objects in a three dimensional space.

    Amazon contended that the patents are invalid under 35 U.S.C. § 101, as applied in Alice Corp. Pty. Ltd v. CLS Bank Int'l, 134 S.Ct. 2347 (2014).  According to Amazon, the asserted claims are directed to the abstract idea of "retrieving and arranging documents," and fail to recite any additional elements that transform the claims into patentable subject matter.

    Abstract Idea?

    In Alice, the Supreme Court set out a two-part test for determining whether a claim is patent-eligible.  The Court must first "determine whether the claims at issue are directed to a patent-ineligible concept."  For computing-related functionality, the inquiry at this first step asks whether the focus of the claims is on the specific asserted improvement in computer capabilities (i.e., the self-referential table for a computer database) or, instead, on a process that qualifies as an abstract idea for which computers are invoked merely as a tool.

    The District Court found that the claims are drawn to the very basic concept of retrieving and arranging documents based on frequency of use.  Despite the repeated use of the word "circuitry," no such circuitry is disclosed in the patents.  The claims in question here are defined only in terms of their functions, which are directed to the abstract idea of retrieving and arranging documents by relative frequency of use.

    TriDim emphasized that the patents are "directed to a computer user interface," but did not explain why or how this label transforms the abstract idea into a patent-eligible invention.

    TriDim also argued that the limitation of dividing a computer display into three spaces confines the invention to a specific system and method and consequently is not an abstract idea.  But the District Court stated "[t]his is mere window dressing" as the patents themselves analogize the "immediate memory" and "tertiary" spaces to a "desk" and a "bookshelf."  This shows that the patents represent nothing more than the abstract idea of placing more frequently used documents in a space that is more easily accessible — an organizational system people intuitively use in a variety of contexts.

    As a final defense, TriDim contended that the patents are not directed to an abstract idea, because the claims were necessarily rooted in computer technology in order to overcome a problem specifically arising in the realm of computer networks.  The District Court dismissed this argument as being misplaced since such reasoning is considered under the second prong of the Alice test, addressing whether there is "an inventive concept".

    Inventive Concept?

    If a patent is directed to a patent-ineligible concept, then the second step of the Alice test requires the Court to search for an "inventive concept" that may save the patent.

    The District Court found that neither the problem Tridim's patents purportedly solve (limited screen space for the display and organization of documents) nor the suggested solution (arranging documents by frequency of use) is "necessarily rooted in computer technology."  In contrast, the District Court contended that storing documents that are less frequently used in a library or on a bookshelf as opposed to on one's desk is a common solution to a common problem of limited space in physical offices everywhere, and that it is hard to picture any office, dorm room, or workspace since the advent of the printing press that did not follow this basic concept of organization.  And since by TriDim's own admission, the patents were "specifically intended to be used with a typical computer," applying a "commonplace" method of organization to a typical computer does not constitute an inventive concept.

    The District Court also found that the elements of the claims that relate to the means of moving and positioning the document objects suffer from the same lack of inventive concept.  According to TriDim, the "touch and drop" and "flicking" gestures were improvements specifically adapted for a 3-D space because known techniques for operating a 2-D workspace such as drag and drop techniques were not efficient.  The District Court found that the patents do not disclose any specific ways, hardware or software, that a user may program or implement these gestures, and that the claims were no more than circular definitions.  The elements that are defined only in terms of their functionalities, whether considered separately or as an ordered combination, fall short of constituting an inventive concept.

    Thus, the District Court found the claims at issue in the '326 patent and the '709 patent to constitute a wholly generic computer implementation of the abstract idea of retrieving and arranging documents based on relative frequency of use.  The motion to dismiss was granted.

    Despite the claims themselves specifically being directed to a "computer controlled display" and including tangible elements, such as "document receiving means," "positioning means," and "workspace display circuitry," the District Court found the claim to be directed to ineligible subject matter.  The problem with the claim, in my opinion, is not that it is directed to ineligible subject matter, but that it fails with respect to section 112 for lack of written description for providing any detail of the "means" elements, or any detail of such "circuitry".  The fact that section 101 is used to invalidate this patent by the District Court seems misplaced.

    Order dismissing the complaint by District Judge James Donato.

  • By Andrew Williams

    AmgenOn Friday, the FDA approved Amgen's application to market Amjevita (adalimumab-atto), a biosimilar to AbbVie's HUMIRA (adalimumab) fully human anti-TNF-α antibody.  This marks the fourth biosimilar approved by the FDA pursuant to the BPCIA.  Amgen submitted Biologics License Application ("BLA") 761024 on November 25, 2015 pursuant to subsection (k) of the BPCIA, which the FDA accepted on or around January 22, 2016.  According to the FDA's press release, Amjevita is approved for the following indications in adult patients:

    • moderately to severely active rheumatoid arthritis;
    • active psoriatic arthritis;
    • active ankylosing spondylitis (an arthritis that affects the spine);
    • moderately to severely active Crohn's disease;
    • moderately to severely active ulcerative colitis; and
    • moderate to severe plaque psoriasis.

    The biosimilar was also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years or older.

    AbbvieNotwithstanding the approval, it is unlikely that Amgen will begin marketing Amjevita anytime soon.  As we previously reported, AbbVie filed suit against Amgen in the U.S. District Court for the District of Delaware on August 4, 2016, pursuant to the BPCIA and 35 U.S.C. § 271(e)(2)(C).  In its Counterclaims and Answer, Amgen reported that it had certified to AbbVie that it would not begin commercial marketing of its biosimilar before at least one of the patents identified by AbbVie had expired on December 31, 2016.  Moreover, Amgen stated several times in its court filing that it intends to fully comply with the 180-day Notice of Commercial Marketing provision of the BPCIA.  This would necessarily delay the launch of Amjevita until at least March of 2017.  Finally, even though the present litigation only encompasses 10 of the 61 patents identified by AbbVie and Amgen during the so-called patent dance, AbbVie suggested multiple times in its complaint that it would seek to enforce the remaining patents once it received commercial-marketing notice from Amgen.  It would not be surprising if AbbVie also sought an injunction from the Court to prevent Amgen from launching before the patent issues have been resolved.  We will continue to monitor the case a report any updates as warranted.    

  • CalendarSeptember 29, 2016 - IP & Diagnostics Symposium (Biotechnology Innovation Organization) – Alexandria, VA

    September 29, 2016 – "Patent Inventorship: Best Practices for Determination and Correction — Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, and Real Party in Interest" (Strafford)

    September 29, 2016 – "Trade Secrets: Strategies for Understanding & Litigating a DTSA Cause of Action" (Wolters Kluwer) – 12:00 pm (ET)

    September 29, 2016 – "Second Medical Use Claims in South African Patent Law" (KISCH IP)

    September 29-30, 2016 – Advanced Patent Law Seminar (Chisum Patent Academy) – Washington, DC

    October 3-4, 2016 – Advanced Patent Law Seminar (Chisum Patent Academy) – Washington, DC

    October 13, 2016 – "Leveraging USPTO Examiner Count System: Efficiently Prosecuting Patents, Lowering Prosecution Costs" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 19, 2016 – "To Patent or Not to Patent: When to Keep Your IP a Trade Secret" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    ***Patent Docs is a media partner of this conference or CLE